<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02800824</url>
  </required_header>
  <id_info>
    <org_study_id>PRG-NY-16-007</org_study_id>
    <nct_id>NCT02800824</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Budesonide Rectal Aerosol Foam and Uceris® Rectal Aerosol Foam</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Perrigo Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Perrigo Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the bioequivalence between the Test Product Budesonide rectal aerosol foam and
      Reference Product Uceris® rectal aerosol foam after a single-dose in healthy subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma drug concentration (Cmax)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time 0 extrapolated to infinity (AUC0-∞)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time 0 to 24 hours (AUC0-24)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Budesonide rectal foam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Uceris rectal foam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide</intervention_name>
    <arm_group_label>Budesonide rectal foam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Uceris</intervention_name>
    <arm_group_label>Uceris rectal foam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy, non-smoking, male and female subjects, 18 years of age or over.

          2. No clinically significant findings in vital signs measurements or 12-lead
             electrocardiogram (ECG) or abnormal laboratory values.

          3. Have no significant diseases.

          4. Willing to use an acceptable, effective method of contraception.

          5. Informed on the nature of the study and have agreed to and are able to read, review
             and sign all consent documents.

          6. Have no clinically significant findings from a physical examination.

        Exclusion Criteria:

          1. Known history or presence of clinically significant neurologic, hematologic,
             endocrine, oncologic, pulmonary, immunologic, genitourinary, psychiatric, or
             cardiovascular disease or any other condition which, in the opinion of the
             Investigator, would jeopardize the safety of the subject or impact the validity of the
             study results

          2. Known history or presence of hypersensitivity or idiosyncratic reaction to budesonide,
             any other components of the drug products, or any other drug substances with similar
             activity or sodium phosphate

          3. History or presence or of diabetes mellitus, glaucoma or cataracts, hypertension, or
             osteoporosis

          4. History of drug or alcohol addiction requiring treatment.

          5. History of malabsorption within the last year.

          6. Presence of hepatic or renal dysfunction.

          7. Presence of a medical condition requiring regular medication (prescription and/or
             over-the-counter) with systemic absorption.

          8. Positive test result for HIV, Hepatitis B surface antigen, or Hepatitis C antibody.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2016</study_first_submitted>
  <study_first_submitted_qc>June 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2016</study_first_posted>
  <last_update_submitted>June 9, 2016</last_update_submitted>
  <last_update_submitted_qc>June 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

